Our COVID19 phase 2 clinical trial for our lead product, rhu-pGSN, has begun.

Share on facebook
Share on twitter
Share on linkedin

August 30, 2012: NIAID Awards BioAegis Therapeutics’ Scientific Advisor Lester Kobzik $1MM Grant to Further Plasma Gelsolin Research

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – August 30, 2012) Lester Kobzik M.D., BioAegis Scientific Advisor and collaborator from Harvard School of Public Health, has made important medical discoveries about plasma gelsolin’s role in boosting immune function to target a broad range of pathogens. Dr. Kobzik is pursuing work in secondary pneumonia under a $1 million NIH grant to support advancement of our plasma gelsolin work.